Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)

Summary

The primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to assess whether treatment with rituximab in patients with MG will: * Allow faster and greater corticosteroid tapering * Reduce the frequency of exacerbations * Improve quality of life * Offer an acceptable safety and tolerability profile.

Timeline

Start

2022-02-28

Primary completion

2025-07-31

Completion

2025-07-31

Drugs

Indications